Quality of life in persons with schizophrenia in out-patient treatment with first- or second-generation antipsychotics

Acta Psychiatrica Scandinavica

Volumn 110, Issue 2, 2004, Pages 108-118

  Kilian, R ^a,c   Dietrich, S ^a   Toumi, M ^b   Angermeyer, M C ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Lundbeck   (France)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

Antipsychotic agents; Longitudinal study; Naturalistic trial; Quality of life; Random effect regression; Schizophrenia

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE;

ADULT; AKATHISIA; AKINESIA; ANTICHOLINERGIC EFFECT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATIGUE; FEMALE; HUMAN; HYPERSALIVATION; MAJOR CLINICAL STUDY; MALE; MUSCLE RIGIDITY; OUTPATIENT; PRIORITY JOURNAL; QUALITY OF LIFE; REGRESSION ANALYSIS; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; TREMOR; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 3242788666     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0047.2004.00332.x     Document Type: Article

References (72)

1. GAITE L, VÄZQUES-BARQUERO JL, BORRA C et al. Quality of life in patients with schizophrenia in five European countries: the EPSILON study. Acta Psychiatr Scand 2002;105:283-292.
2. HANSSON L, MIDDELBOE T, SORGAARD KW et al. Living situation, subjective quality of life and social network among individuals with schizophrenia living in community settings. Acta Psychiatr Scand 2002;105:343-350.
3. HANSSON L, MIDDELBOE T, MERINDER L et al. Predictors of subjective quality of life in schizophrenic patients living in the community. A nordic multicentre study. Int J Soc Psychiatr 1999;45:247-258.
4. KEMMLER G, MEISE U, TASSER A et al. Quality of life in schizophrenia: relationships to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand 1994;89:118-124.
5. BROWNE S, ROE L, GERVIN M et al. Quality of life in schizophrenia: Relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand 1996;94:118-124.
6. PACKER S, HUSTED J, COHEN S et al. Psychopathology and quality of life in schizophrenia. J Psychiatry Neurosci 1997; 22:231-233.
7. RITSNER M, PONIZOVSKY A, ENDICOTT J et al. The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study. Eur Psychopharmacol 2002;12:31-38.
8. GERLACH J, LARSEN EB. Subjective experience and mental side-effects of antipsychotic treatment. Acta Psychiatr Scand 1999;99:113-117.
9. LARSEN EB, GERLACH J. Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot-neuroleptics. Acta Psychiatr Scand 1996;93:381-388.
10. ANGERMEYER MC, KATSCHNIG H. Psychotropic medication and quality of life: a conceptual framework for assessing their relationships. In: KATSCHNIG H, FREEMAN H, SARTORIUS N, eds. Quality of life in mental disorders. Chichester: Wiley, 1997:215-225.
11. GLAZER WM. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatr 2000;61(suppl. 4):21-26.
12. NABER D, MORITZ S, LAMBERT M et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001;50:79-88.
13. NABER D, KAROW A. Good tolerability equals good results: the patients perspective. European Neuropharmacology 2001;11(suppl. 4):S391-S396.
14. BURNS T, BALE R. Clinical advantages of amilsupride in the treatment of acute schizophrenia. J Int Med Res 2001; 29:451-466.
15. BOBES J, GUTIÉRREZ M, GIBERT J et al. Quality of life in schizophrenia: long-term follow-up in 362 chronic Spanish schizophrenic outpatients undergoing risperidone maintenance treatment. Eur Psychiatr 1998;13:158-163.
16. COOK PE, GOLDBERG JO, VAN LIESHOUT RJ. Benefits of switching from typical to atypical antipsychotic medications: a longitudinal study in a community based setting. Can J Psychiatry 2002;47:870-874.
17. FRANZ M, LIS S, PLÜDDEMANN K et al. Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Br J Psychiatry 1997;170:423-425.
18. AWAD AG, VORUGANTI L. Quality of life and new antipsychotics in schizophrenia. Are patients better off? Int J Soc Psychiatr 1999;45:268-275.
19. NABER D, LAMBERT M. Sertindole decreases hospitalization and improves the quality of life of schizophrenic patients. Int J Psychiatr Clin Practice 1998;2(suppl. 2):S73-S77.
20. REVICKI DA, GENDUSO LA, HAMILTON SH et al. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized trial. Qual Life Res 1999;8:417-426.
21. COLONNA L, SALEEM P, DONDEY-NOUVEL L et al. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Int Clin Psychopharm 2000;15:13-22.
22. CARRIÈRE P, BOHNOMME D, LEMÉRIÈRE T. Amisulpride has a superior benefit/risk profile to haloperiodol in schizophrenia: results of a multicentre double-blind study. Eur Psychiatr 2000;15:321-329.
23. VORUGANTI L, CORTESE L, OYEWUMI L et al. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000; 43:135-145.
24. VORUGANTI L, CORTESE L, OWYEUMI L et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 2002;57:201-208.
25. AWAD AG, LAPIERRE YD, ANGUS C et al. Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. J Psychiatry Neurosci 1997;4:244-248.
26. HAMILTON SH, REVICKI DA, GENDUSO LA. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 1998;18:41-49.
27. HAMILTON SH, REVICKI DA, EDGELL ET et al. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomized clinical trial. Pharmacoeconomics 1999;15:469-480.
28. STALLARD J, JOYCE E. The impact of olanzapine on attitude to medication and quality of life in schizophrenia. Psychiatr Bull 2001;25:378-381.
29. AWAD AG, HOGAN TP, VORUGANTI LPN et al. Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharm 1995;10(suppl. 3):123-132.
30. AWAD AG. Subjective response to neuroleptics in schizophrenia. Schizopr Bull 1993;19:609-618.
31. BROWNE S, CARAVAN J, GERVIN M et al. Quality of life in schizophrenia: insight and subjective response to neuroleptics. J Nerv Ment Dis 1998;186:74-78.
32. DOYLE M, FLANNAGAN S, BROWNE S et al. Subjective and external assessments of quality of life in schizophrenia: relationship to insight. Acta Psychiatr Scand 1999;99:466-472.
33. HOLLOWAY F, CARSON F. Subjective quality of life, psychopathology, satisfaction with care and insight: an exploratory study. Int J Soc Psychiatr 1999;45:259-267.
34. CLARK RE, BARTELS SJ, MELLMAN TA et al. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizopr Bull 2002;28:75-84.
35. PAPPADOPULOS E, JENSEN PS, SCHUR SB et al. "Real world" atypical antipsychotic prescribing practices in public child and adolescent inpatient settings. Schizopr Bull 2002; 28:111-121.
36. WEISSMAN EM. Antipsychotic prescribing practices in the veterans healthcare administration - New York Metropolitan region. Schizopr Bull 2002;28:31-42.
37. MILLER AL, CRAIG CS. Combination antipsychotics: pros, cons and questions. Schizopr Bull 2002;28:105-109.
38. FREUDENREICH O, GOFF C. Antipsychotic combination therapy in schizophrenia. A review of efficay and risk of current combinations. Acta Psychiatr Scand 2002;106:323-330.
39. WING JK, BABOR T, BRUGHA T et al. SCAN: Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatr 1990;47:589-593.
40. LEHMAN AF. A quality of life interview for the chronically mentally ill. Evaluation Prog Planning 1988;11:51-62.
41. LAUER G, STEGMULLER-KOENENMUND U. Domain-specific subjective quality of life and illness-related limitations of chronic schizophrenic patients (Bereichsspezifische subjektive lebensqualität und krnakheitsbedingte Einrschränkungen chronisch schizophrener Patienten). Psychiat Prax 1994; 21:70-73.
42. Russo J, ROY-BYRNE P, REEDER D et al. Longitudinal assessment of quality of life in acute psychiatric inpatients: reliability and validity. J Nerv Ment Dis 1997;185: 166-175.
43. CHISHOLM D, KNAPP M, KNUDSEN HC et al. Client sociodemographic and service receipt inventory - European version. Br J Psychiatry 2000;177(suppl. 39):S28-S33.
44. ROICK C, KILIAN R, MATSCHINGER H et al. Die Deutsche Version des Client Sociodemographic Service Receipt Inventory (CSSRI-EU) (German adaptation of the Client Sociodemographic and Service Receipt Inventory). Psychiat Prax 2001;28(Sonderheft 2):S84-S90.
45. KAY SR, OPLER LA, LINDEMEYER JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry 1989;155:59-65.
46. MÜLLER MJ, ROSSBACH W, DAVIDS E et al. Evaluation of standardized rater training for the Positive and Negative Syndrome Scale (PANSS) (Evaluation eines standardiseirten Trainings für die "Positive und Negative Syndrome Scale" (PANSS). Nervenarzt 2000;71:195-204.
47. ADDINGTON D, ADDINGTON J, SCHISSEL B. Reliability and validity of a depression rating scale for schizophrenia. Schizophr Res 1990;3:247-251.
48. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-III-R), 3rd edn. Washington DC: APA, 1987.
49. BARNES T. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676.
50. GRUBER O, NORTHOFF G, PFLUG B. Subjective experiences of patients with acute neuroleptic-induced akathisia. Fortschr Neurol Psychiatr 1998;66:531-538.
51. SIMPSON G, ANGUS J. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212:11-19.
52. MATTKE DJ, MOBOUR W, GLOTZNER FL. The assessment of neuroleptogenic extrapyramidal syndromes in psychopharmacological research. Pharmakopsychiatr Neuropsychopharmakol 1975;1:36-44.
53. GUY W. ECDU assessment manual for psychopharmacology. Rockville, MD: U.S. National Institute of Health, Psychopharmacology Research Branch, 1976.
54. MILLER CH, SIMIONI I, OBERBAUER H et al. Tardive dyskinesia prevalence rates during a ten-year follow-up. J Nerv Ment Dis 1995;183:404-407.
55. BALTAGI BH, WU PX. Unequal spaced panel data regressions with AR(1) disturbances. Econometr Theory 1999; 15:814-823.
56. BALTAGI BH. Econometric analysis of panel data. Chichester, New York: John Wiley & Sons, 2001.
57. WOOLDRIDGE JM. Econometric analysis of cross section and panel data. Cambridge: MIT Press, 2002.
58. Stata Corporation Stata reference manual, Release 7. College Station, TX: Stata Press, 2001.
59. EFRON B, TIBSHIRANI R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci 1986;1:54-77.
60. D'AGOSTINO RB. Tutorial in biostatistics. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-2281.
61. GREENE WH. Econometric analysis, 5th edn. Upper Saddle River: Prentice Hall, 2003.
62. POLISSAR L, DIEHR P. Regression analysis in health services research: the use of dummy variables. Med Care 1982;20:959-966.
63. KILIAN R, MATSCHINGER H, BECKER T et al. A longitudinal analysis of the impact of social and clinical characteristics on the costs of schizophrenia treatment. Acta Psychiatr Scand 2003;107:351-360.
64. HEDEKER D, GIBBONS JS, WATERNAUX C. Sample size estimation for longitudinal designs with attrition: comparing time-related constrasts between two groups. J Educ Behav Stat 1999;24:70-93.
65. DIGGLE PJ, HEAGERTY P, LIANG K-Y et al. Analysis of longitudinal data, 2nd edn. Oxford: Oxford University Press, 2002.
66. LINDSEY PJ. Adapting sample size calculations to repeated measurements in clinical trials. J Appl Stat 2001;28:81-89.
67. JUNG S-H, AHN C. Sample size estimation for GEE method for comparing slopes in repeated measurements data. Stat Med 2003;22:1305-1315.
68. COHEN J. Statistical power analysis for the behavioral sciences, 2nd edn. Hillsdale: Lawrence Erlbaum Associates, 1988.
69. LESLIE DL, ROSENHECK R. Shifting to outpatient care? Mental health care use and cost under private insurance. Am J Psychiatr 1999;156:1250-1257.
70. AN DER HEIDEN W, HÄFNER H. The epidemiology of onset and course of schizophrenia. Eur Arch Psychiatr Clin Neurosci 2000;250:292-303.
71. ANGERMEYER MC, LÖFFLER W, MÜLLER P et al. Patients' and relatives' assessment of clozapine treatment. Psychol Med 2001;31:509-517.
72. HÄFNER H, AN DER HEIDEN W. The course of schizophrenia in the light of modern follow-up studies: the ABC and WHO studies. Eur Arch Psychiatr Clin Neurosci 1999;249:IV/14-IV/26.